PersonalisPSNL
PSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 229
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
89% more capital invested
Capital invested by funds: $158M [Q3] → $298M (+$141M) [Q4]
28% more funds holding
Funds holding: 83 [Q3] → 106 (+23) [Q4]
17.54% more ownership
Funds ownership: 55.11% [Q3] → 72.65% (+17.54%) [Q4]
6% less call options, than puts
Call options by funds: $482K | Put options by funds: $511K
31% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 35
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
122%
upside
Avg. target
$7.67
143%
upside
High target
$8
153%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target | 122%upside $7 | Buy Reiterated | 10 Apr 2025 |
Craig-Hallum John Wilkin 0% 1-year accuracy 0 / 3 met price target | 153%upside $8 | Buy Initiated | 17 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 20% 1-year accuracy 38 / 192 met price target | 153%upside $8 | Buy Reiterated | 28 Feb 2025 |
Financial journalist opinion
Positive
Investors Business Daily
4 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Neutral
Business Wire
3 weeks ago
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the.
Neutral
Business Wire
1 month ago
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ult.
Neutral
Seeking Alpha
1 month ago
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
Negative
Zacks Investment Research
1 month ago
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.
Neutral
Business Wire
1 month ago
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024.
Positive
Seeking Alpha
1 month ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Negative
Zacks Investment Research
1 month ago
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
2 months ago
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025, at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guidi.
Positive
Seeking Alpha
2 months ago
Exciting Technology At Personalis, But Profitability Eludes Them
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.
Charts implemented using Lightweight Charts™